Kenya Medical Supplies Authority Commercial Street Industrial Area Pharmaceutical Import Profile — Kenya (DGFT 2022–2026)

Name: Kenya Medical Supplies Authority Commercial Street Industrial Area Pharmaceutical Import Records from India — 2 Products, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kenya Medical Supplies Authority Commercial Street Industrial Area — Pharmaceutical Importer Profile (2026) | 2 Products, $200.0K Trade | TransData Nexus

Kenya Medical Supplies Authority Commercial Street Industrial Area

Pharmaceutical Importer · Kenya · Antiviral & HIV Medications Focus · $200.0K Total Trade · DGFT Verified

Kenya Medical Supplies Authority Commercial Street Industrial Area is a pharmaceutical importer based in Kenya with a total trade value of $200.0K across 2 products in 1 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Kenya Medical Supplies Authority Commercial Street Industrial Area sources from 1 verified Indian supplier, with Emcure Pharmaceuticals Limited accounting for 100.0% of imports.

Kenya Medical Supplies Authority Commercial Street Industrial Area — Import Portfolio & Supplier Network

Kenya Medical Supplies Authority Commercial Street Industrial Area import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Kenya Medical Supplies Authority Commercial Street Industrial Area?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$350.0K	7	100.0%

Kenya Medical Supplies Authority Commercial Street Industrial Area sources from 1 verified Indian supplier across 4 distinct formulations. The sourcing is highly concentrated — Emcure Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharmaceutical article / ods / product / item finished goods- viropil 50/300/300MG tablet 90s dolutegravir lamivudine & tenofovir	$200.0K	4
Pharmaceutical article / ods / product / item finished goods:-atazor r 300/100MG tablet 30s atazanavir & ritonavir USP tablets 300/100MG	$50.0K	1
Pharmaceutical article / ods / product / item finished goods- viropil 50/300/300MG tablet 90s dolutegravir, lamivudine & tenofovir	$50.0K	1
Pharmaceutical article / ods / product / item finished goods- atazor r 300/100MG tablet 30s atazanavir & ritonavir USP tablets 300/100MG	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atazanavir	Antiviral & HIV Medications	$100.0K	2	0.1%	6
2	Ritonavir	Antiviral & HIV Medications	$100.0K	2	0.0%	15

Kenya Medical Supplies Authority Commercial Street Industrial Area imports 2 pharmaceutical products across 1 categories into Kenya totaling $200.0K.

Kenya Medical Supplies Authority Commercial Street Industrial Area — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Kenya Medical Supplies Authority (KEMSA) is a state corporation under the Ministry of Health, established by the KEMSA Act of 2013. Its primary mandate is to procure, warehouse, and distribute health products and technologies for public health programs, national strategic stock reserves, essential health packages, and national referral hospitals. KEMSA's vision is to provide quality, affordable essential health products and supply chain solutions to save and transform lives within the East African region. (kemsa.go.ke)

Historically, KEMSA's headquarters were located along Commercial Street in Nairobi's Industrial Area. However, in May 2024, the authority relocated its headquarters to the National Supply Chain Centre in Embakasi, Nairobi, aiming to centralize operations and enhance service delivery. (kemsa.go.ke)

2Distribution Network

KEMSA operates a comprehensive distribution network across Kenya, ensuring the efficient delivery of medical commodities to public health facilities. The authority's main warehouse is situated at the National Supply Chain Centre in Embakasi, Nairobi. Additionally, KEMSA maintains regional depots in Kisumu, Eldoret, Nyeri, and Mombasa, strategically located to serve various regions of the country. (kemsa.go.ke)

The distribution network is supported by a fleet of vehicles and partnerships with logistics service providers, facilitating timely and reliable delivery of health products to health institutions nationwide. This extensive network underscores KEMSA's commitment to ensuring the availability of essential medical supplies across Kenya.

3Industry Role

KEMSA plays a pivotal role in Kenya's pharmaceutical supply chain as the primary wholesaler and distributor of medical commodities to public health facilities. By centralizing procurement and distribution, KEMSA ensures that public health programs, national strategic stock reserves, and essential health packages are adequately supplied. This centralized approach enhances efficiency and cost-effectiveness in the delivery of health products and technologies. (kemsa.go.ke)

While KEMSA's primary focus is on public health facilities, its operations indirectly influence the broader pharmaceutical market in Kenya, including private sector suppliers and distributors. The authority's procurement decisions and distribution strategies can impact market dynamics, pricing, and availability of medical commodities across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Kenya Medical Supplies Authority Commercial Street Industrial Area

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

KEMSA's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, EMCURE Pharmaceuticals Limited. Between 2022 and 2026, KEMSA imported finished pharmaceutical formulations totaling $200,000 USD across four shipments, all sourced from EMCURE Pharmaceuticals Limited. This supplier concentration indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chains.

However, this single-source dependency also presents risks, including vulnerability to supply disruptions, price fluctuations, and potential challenges in negotiating better terms. The absence of alternative suppliers in KEMSA's procurement strategy suggests a need for diversification to mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

KEMSA's supply chain resilience is closely tied to its reliance on EMCURE Pharmaceuticals Limited as the sole supplier for its pharmaceutical imports. This concentrated sourcing strategy may expose KEMSA to risks such as supply disruptions, regulatory changes affecting the supplier, or geopolitical issues impacting trade routes.

To bolster supply chain resilience, KEMSA could consider diversifying its supplier base, establishing relationships with multiple manufacturers, and developing contingency plans to address potential disruptions. Additionally, ensuring that suppliers adhere to international quality standards and maintaining compliance with regulatory requirements are crucial steps in strengthening the overall supply chain.

Importing Pharmaceuticals into Kenya — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Kenya

1Regulatory Authority & Framework

In Kenya, the Pharmacy and Poisons Board (PPB) serves as the primary regulatory authority overseeing the importation, distribution, and sale of pharmaceutical products. The PPB ensures that all medical commodities meet the required safety, efficacy, and quality standards before they are permitted for use within the country.

Key legislation governing pharmaceutical imports into Kenya includes the Pharmacy and Poisons Act, which outlines the regulatory framework for the control and management of pharmaceutical products. Additionally, the Food, Drugs and Chemical Substances Act provides guidelines on the importation and control of drugs and related substances. These regulations are designed to safeguard public health by ensuring that only approved and safe pharmaceutical products are available in the Kenyan market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Kenya are stringent, necessitating that all imported drugs and medical supplies be registered with the Pharmacy and Poisons Board. This registration process involves the submission of detailed product information, including manufacturing processes, quality control measures, and clinical data, to demonstrate compliance with Kenyan standards.

Good Manufacturing Practice (GMP) certification is a critical component of the import licensing process. The PPB recognizes GMP certifications from reputable authorities, including the World Health Organization (WHO) and the European Union (EU). Manufacturers seeking to export pharmaceutical products to Kenya must provide evidence of GMP compliance from these recognized bodies to ensure that their products meet the required quality standards.

Kenya Medical Supplies Authority Commercial Street Industrial Area — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

KEMSA's focus on importing antiviral and HIV medications, specifically Atazanavir and Ritonavir, aligns with the high prevalence of HIV/AIDS in Kenya. These imports are driven by the national commitment to providing comprehensive HIV treatment and care services to the population. The demand for these medications is substantial, necessitating a reliable supply chain to ensure uninterrupted access for patients.

The strategic emphasis on these therapeutic areas underscores KEMSA's role in supporting public health initiatives aimed at controlling and managing HIV/AIDS within the country.

2Sourcing Profile

KEMSA's sourcing strategy for antiviral and HIV medications is heavily reliant on a single supplier, EMCURE Pharmaceuticals Limited. This approach suggests a strategic partnership, potentially offering benefits such as favorable pricing and consistent product quality. However, the lack of diversification in the supplier base may expose KEMSA to risks associated with supply disruptions or changes in supplier terms.

To mitigate these risks, KEMSA could consider expanding its supplier network to include multiple manufacturers, thereby enhancing supply chain resilience and ensuring a more robust procurement strategy.

3Market Positioning

Seller's Guide — How to Become a Supplier to Kenya Medical Supplies Authority Commercial Street Industrial Area

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to enter the Kenyan market by meeting KEMSA's stringent quality and regulatory requirements. Diversifying KEMSA's supplier base could lead to competitive advantages, including improved pricing and enhanced supply chain resilience.

Identifying and addressing any gaps in KEMSA's current sourcing strategy, such as the need for alternative suppliers or additional product formulations, could present valuable opportunities for Indian exporters.

2Requirements & Qualifications

Indian exporters seeking to supply

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Kenya Medical Supplies Authority Commercial Street Industrial Area

What products does Kenya Medical Supplies Authority Commercial Street Industrial Area import from India?

Kenya Medical Supplies Authority Commercial Street Industrial Area imports 2 pharmaceutical products across 1 categories. Top imports: Atazanavir ($100.0K), Ritonavir ($100.0K).

Who supplies pharmaceuticals to Kenya Medical Supplies Authority Commercial Street Industrial Area from India?

Kenya Medical Supplies Authority Commercial Street Industrial Area sources from 1 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (100.0% of imports, $350.0K).

What is Kenya Medical Supplies Authority Commercial Street Industrial Area's total pharmaceutical import value?

Kenya Medical Supplies Authority Commercial Street Industrial Area's total pharmaceutical import value from India is $200.0K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Kenya Medical Supplies Authority Commercial Street Industrial Area focus on?

Kenya Medical Supplies Authority Commercial Street Industrial Area imports across 1 categories. The largest: Antiviral & HIV Medications (100.0%).

Get Full Kenya Medical Supplies Authority Commercial Street Industrial Area Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.